CalciMedica (NASDAQ:CALC) Given Buy Rating at HC Wainwright

CalciMedica (NASDAQ:CALC)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports. They currently have a $16.00 price target on the stock.

CalciMedica Stock Performance

CalciMedica stock opened at $2.13 on Tuesday. The company has a market capitalization of $28.72 million, a PE ratio of -1.97 and a beta of 1.20. CalciMedica has a fifty-two week low of $1.86 and a fifty-two week high of $6.27. The firm has a 50 day moving average price of $2.77 and a 200 day moving average price of $3.44.

Institutional Trading of CalciMedica

Large investors have recently made changes to their positions in the company. Cetera Investment Advisers raised its position in shares of CalciMedica by 37.1% during the 4th quarter. Cetera Investment Advisers now owns 16,873 shares of the company’s stock worth $60,000 after acquiring an additional 4,566 shares in the last quarter. PVG Asset Management Corp purchased a new position in CalciMedica during the 3rd quarter worth approximately $67,000. Atria Investments Inc increased its position in CalciMedica by 136.5% during the third quarter. Atria Investments Inc now owns 26,503 shares of the company’s stock worth $117,000 after buying an additional 15,296 shares during the period. Corient Private Wealth LLC acquired a new position in CalciMedica during the fourth quarter worth approximately $135,000. Finally, Renaissance Technologies LLC purchased a new stake in CalciMedica in the fourth quarter valued at approximately $153,000.

About CalciMedica

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.